Farrington Presents at BIO2003 on Big Pharma Spin-Offs that Work

June 30, 2003

Wiggin & Dana Biotechnology and Life Sciences Practice Group Chair James Farrington, Jr. presented at a session of this year’s BIO2003 conference, held June 22-25th.  The topic was spin-offs from pharmaceutical companies, including those that result from consolidation of operations following a merger.  Farrington outlined what works when structuring these transactions, pointing out some of the key elements of several recent successful spin-offs, including that of Wiggin & Dana client Pharmacia Corporation, in the spin-off of Biovitrum AB – a Stockholm based biotechnology company.

Jim Farrington chairs the firm's Biotechnology and Life Sciences Practice Group, and serves as a member of the firm's Executive Committee.  In March 2003, Jim was selected by Global Counsel 3000 as one of nine “highly recommended” U.S. lawyers in corporate partnering and was specifically recognized for his extensive U.S. and European experience encompassing joint ventures, licensing and finance issues.

"With record attendance, international media coverage, a keynote speech by President Bush and an unprecedented number of U.S. and foreign government leaders, BIO 2003 closed with a new level of recognition of the contributions biotech has made to human health and the U.S. economy," said Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO).

Founded in New Haven, Conn. in 1934 with predecessor firms dating back to the 19th century, Wiggin & Dana has more than 150 attorneys in four offices. The firm’s expertise includes all forms of litigation and dispute resolution, complex corporate transactions, antitrust, real estate, environmental and land use law, labor and employment, benefits, health care, and estate planning and administration.  For more information about the firm please visit www.wiggin.com or www.CTbiotechlaw.com.